Infringement Analysis in Brussels.

A patent infringement analysis Brussels litigators can rely on has to be scoped for two forums that sit side by side in the same city — the Brussels Enterprise Court, which holds exclusive national jurisdiction over Belgian patents, and the Brussels local division of the Unified Patent Court. Brussels is the capital of Belgium and of the Brussels-Capital Region, the seat of the EU institutions, and the headquarters of some of Europe’s most patent-active companies, from the biopharmaceutical group UCB to the chemicals multinational Solvay. The patents asserted here read on drug formulations, biologics, chemical processes, logistics systems and connected devices, and each case turns on proof that the accused product actually practises the claim. PerspireIP builds the claim charts and evidence-of-use that establish — or defeat — that link.

Where a patent infringement analysis Brussels case is decided

Belgium concentrates all of its patent litigation in a single city. By statute the Brussels Enterprise Court (Ondernemingsrechtbank Brussel / Tribunal de l’entreprise de Bruxelles) has exclusive national jurisdiction over patent disputes — wherever in the country the alleged infringement happens, the case is filed in Brussels. The court hears matters through both a Dutch-language and a French-language chamber, and litigants proceed in the language of the summons. This centralisation has built a specialised bench that sees the full national stream of pharmaceutical, chemical and technology patent cases.

Appeals rise to the Brussels Court of Appeal (Hof van beroep te Brussel / Cour d’appel de Bruxelles), and a final appeal on points of law lies to the Court of Cassation. Crucially, Belgium runs no bifurcation system: infringement and validity are decided together in one proceeding, and an accused party almost always files a counterclaim for revocation in the same action. Because a single judge weighs both, the mapping that proves the accused product reads on the claim has to be litigation-ready from the first filing.

• Brussels Enterprise Court (Ondernemingsrechtbank / Tribunal de l’entreprise) — exclusive first-instance forum for all Belgian patent disputes, with Dutch- and French-language chambers
• Brussels Court of Appeal (Hof van beroep / Cour d’appel) — the appellate bench that reviews patent judgments
• Court of Cassation (Hof van Cassatie / Cour de cassation) — the final instance on points of law
• OPRI / DIE — the Belgian Office for Intellectual Property that grants the national patents being enforced

Two courts in one city: the Brussels UPC local division

What sets Brussels apart from most European venues is that a second patent court now sits in the same city. On 1 June 2023 the Unified Patent Court opened, and a Brussels local division was established on the premises of the FPS Economy to give Belgian businesses and SMEs direct access to the new system. Belgium is a full UPC member and a Unitary Patent state, so a patentee can obtain a single unitary patent covering Belgium and enforce it here with a pan-European injunction — the opposite of countries such as Spain that stayed outside the UPC and can only be reached through national rights.

The Brussels local division conducts proceedings in Dutch, French, German or English, a rare four-language flexibility that lets international parties litigate in English while a Belgian defendant can insist on a national language. It is presided over by a Belgian permanent judge and draws on the UPC’s multinational panels. Its decisions on classic European patents (unless opted out) and on unitary patents carry effect across all participating member states, not just Belgium.

For an infringement analysis the choice of forum is now strategic. A rights-holder can assert a European patent nationally before the Brussels Enterprise Court, or reach for cross-border relief through the Brussels UPC division; an accused party has to model both threats at once. The same claim chart may need to satisfy Belgian national procedure and the UPC’s rules, so the analysis is built to be portable between the two courts that share the city.

Saisie-contrefaçon: Belgium’s evidence-gathering weapon

Belgium gives a patentee one of Europe’s most powerful pre-suit tools to build the very evidence an infringement analysis needs: the saisie-contrefaçon (in Dutch, beslag inzake namaak), or descriptive seizure. On an ex parte request the President of the Brussels Enterprise Court can appoint an independent expert to enter the alleged infringer’s premises, inspect products, machinery and documents, and prepare a detailed descriptive report — often before the target knows a dispute exists.

The threshold is deliberately low but precise. The patentee must show the patent is prima facie valid and offer indications — not proof — that infringement has occurred or is threatened. Belgian case law has confirmed that a saisie can even be carried out at the premises of a third party, such as a subcontractor of the alleged infringer, which makes it invaluable where the infringing act happens deep inside a supply chain or a manufacturing plant.

A descriptive seizure is only as good as the claim mapping behind it. The judge granting the measure, and the expert executing it, need a clear, element-by-element explanation of what to look for and why it matters to the asserted claim. That is why our claim chart is prepared before the saisie is requested: it defines the scope of the inspection, protects against fishing-expedition objections, and turns the expert’s report into evidence that reads directly onto the patent.

Brussels’ industrial base: what the asserted patents claim

Brussels’ litigation profile is written by the industries clustered in and around the capital. Belgium punches far above its size in pharmaceuticals and biotech — the country is one of Europe’s leading exporters of medicines, and the biopharmaceutical group UCB is headquartered in Brussels, while Janssen Pharmaceutica sits nearby in the Flemish life-sciences corridor. Pharma is Belgium’s most litigated patent field, and the asserted claims read on formulations, biologics and biosimilars, salts and polymorphs, second-medical-use indications and manufacturing processes.

A second stream flows from chemicals and materials. The multinational Solvay is headquartered in Brussels, anchoring a dense specialty-chemicals and advanced-materials sector whose patents cover compositions and processes where infringement often hides inside a production line. Recent Brussels saisie and injunction decisions have turned on exactly these fields, including vaccines and biosimilar products.

A third stream is driven by Brussels’ role as the seat of the EU institutions and a major logistics and regulatory hub. The city’s connected-device, software and logistics-technology companies file portfolios on systems that are hard to inspect without the descriptive seizure. Whether the technology is a biologic, a chemical process, a logistics platform or a connected device, the commercial question is identical: does the accused product or process fall within the scope of the asserted claim? Answering it is exactly what an infringement analysis does.

How a patent infringement analysis Brussels action turns on claim charts

Whether you are asserting a patent or defending against one, a Belgian case is won or lost on a single document: the claim chart that maps each element of the asserted claim onto the accused product or process. Before the Brussels Enterprise Court, and before the Brussels UPC division, the court expects that mapping to be concrete — tied to the marketed formulation, the plant process, the logistics system or the device firmware — and backed by evidence-of-use that survives cross-examination and the revocation counterclaim that runs in the same action.

• Element-by-element claim charts mapping every limitation of the asserted claim to the accused product or process
• Evidence-of-use built from product teardowns, laboratory analysis, technical datasheets, regulatory dossiers and public technical literature
• Doctrine-of-equivalents analysis where the accused product is not a literal match, argued to Belgian and EPC standards
• Non-infringement and freedom-to-operate positions for an accused Belgian manufacturer, with claim construction pinned to the prosecution history
• A package scoped to the forum — a Brussels Enterprise Court complaint, a UPC action, a preliminary injunction, or the basis for a saisie-contrefaçon

The analysis cuts both ways. For a patentee it converts a suspicion into a pleadable infringement case, supports the urgency needed for interim relief, and defines the scope of a descriptive seizure. For an accused pharma, chemical or logistics company it builds the non-infringement read that keeps a product on the market and frames the validity defence that runs in the same proceeding. Either way the decisive input is a rigorous, evidence-backed claim chart — not a conclusion asserted without proof.

How PerspireIP builds a Brussels infringement-analysis file

Every engagement follows the same disciplined path. We construct the claim scope first, fixing the correct construction from the claims, specification and prosecution history, then map each element against the real accused product or process. For pharma we work from formulations, biologic and polymorph data and regulatory dossiers; for chemicals from process and composition evidence; for logistics and connected devices from teardowns, firmware and technical datasheets — charting infringement literally and, where needed, under the doctrine of equivalents.

• Claim construction and element-by-element charting to Belgian and EPC standards
• Evidence-of-use assembly — teardowns, lab analysis, datasheets, regulatory and public technical sources — dated and documented
• Infringement and non-infringement positions built for either side of a Brussels Enterprise Court or UPC dispute
• Deliverables scoped to your forum: a national complaint, a UPC action, a preliminary injunction, or the evidence base for a saisie-contrefaçon
• Coordination across the national and UPC tracks and, where the family is European, with parallel proceedings abroad

We work alongside your Belgian and European counsel as a specialist analysis partner, deliver to Brussels Enterprise Court, UPC and OPRI deadlines, and keep every engagement confidential. Whether you are a Belgian pharma, chemical or logistics company enforcing a patent, an accused party clearing a path to market, or litigation counsel preparing a complaint or a defence, we scale to fit — a single claim chart, a multi-patent matter or ongoing portfolio support. Send us the patent number and the accused product, and we will scope a patent infringement analysis Brussels project within one business day.

IP Landscape & Resources in Brussels

Key intellectual-property authorities and venues relevant to Brussels:

• OPRI / DIE (Belgian Office for Intellectual Property) — the Belgian national IP office within the FPS Economy that grants national patents and validates European patents for Belgium
• Unified Patent Court — the court whose Brussels local division opened on 1 June 2023 and hears unitary and European patent disputes with effect across participating member states
• European Patent Office (EPO) — grants the European and unitary patents enforced in Belgium before the Brussels Enterprise Court and the Brussels UPC local division
• Belgian Federal Justice (Rechtbanken-Tribunaux) — the official portal of the Belgian courts, including the Brussels Enterprise Court that holds exclusive national jurisdiction over patent disputes

Request a Patent Infringement Analysis in Brussels

Explore related PerspireIP services: Patent Infringement Analysis · Prior Art Litigation Search · Patent Invalidation.

Frequently Asked Questions